PubMed Health⌕ Search

Biomedical subjects

Alina Borkowska

Publications and source records attributed to Alina Borkowska.

At least 19 recordsLinked to original sources
PubMed2006

Performance on the Wisconsin Card Sorting Test in schizophrenia and genes of dopaminergic inactivation (COMT, DAT, NET).

The aim of the study was to test an association between polymorphisms of genes connected with dopaminergic inactivation in prefrontal cortex [catechol-O-methyltransferase (COMT), dopamine transporter (DAT), norepinephrine transporter (NET)], and performance on the Wisconsin Card Sorting Test (WCST), in schizophrenic patients. The number of perseverative errors (WCST-P), non-perseverative errors (WCST-NP), completed corrected categories (WCST-CC), conceptual level responses (WCST-%CONC) and set to the first category (WCST-1st CAT) were measured. Genotyping was done for the Val108(158)Met polymorphism of the COMT gene (79 patients), the 3'UTR VNTR polymorphism of the DAT gene (124 patients) and the 1287 A/G polymorphism of the NET gene (63 patients). Male schizophrenic patients with Val/Val genotype of COMT obtained better results on WCST-P, while female patients had worse results on the WCST-NP compared with the remaining genotypes. There was a slight trend for patients with the A9/A9 genotype of DAT and with the A/A genotype of NET to perform better on some domains of the WCST, compared with other genotypes. A limitation to the interpretation of results could be small number of patients studied as well as variable psychopathological state and medication during cognitive testing.

Adolescent↗
PubMed2006

Prefrontal cognition in schizophrenia and bipolar illness in relation to Val66Met polymorphism of the brain-derived neurotrophic factor gene.

The measures of prefrontal cognition have been used as endophenotype in molecular-genetic studies. Brain-derived neurotrophic factor (BDNF) has been implicated in cognitive functions and in the pathogenesis of major psychoses. This study investigates the relationship between Val66Met polymorphisms of the BDNF gene and prefrontal cognitive function in 129 patients with schizophrenia and 111 patients with bipolar mood disorder. Cognitive tests included the Wisconsin Card Sorting Test (WCST), with such domains as number of perseverative errors, non-perseverative errors, completed corrected categories, conceptual level responses, and set to the first category, and the N-back test, where mean reaction time and percent of correct reactions were measured. Genotyping for Val66Met BDNF polymorphism was done by polymerase chain reaction method. In schizophrenia, no relationship between Val66Met polymorphism of the BDNF gene and the results of the WCST was observed. Patients with Val/Val genotype had a higher percentage of correct reactions in the N-back test than those with the remaining genotypes. Bipolar patients with Val/Val genotype obtained significantly better results on three of five domains of the WCST. No relationship between BDNF polymorphism and the results of the N-back test was found in this group. A limitation to the results could be variable psychopathological state and medication during cognitive testing and lack of Hardy-Weinberg equilibrium in schizophrenia group. Val66Met polymorphism of the BDNF gene may be associated with cognitive performance on the WCST in bipolar mood disorder but not in schizophrenia. An association of this polymorphism with performance on the N-back test in schizophrenia and not in bipolar illness may suggest that in schizophrenia, the BDNF system may be connected with early phases of information processing.

Adolescent↗
PubMed2006

[Marchiafava-Bignami disease].

Marchiafava-Bignami disease (MBD) is a rare central nervous system disorder of an unknown etiology strongly associated with alcoholism. MBD primarily affects the corpus callosum leading to confusion, dysarthria, seizures and frequently to death. About 250 cases of different races and nationalities, mostly alcoholics have been reported. We report a single-case study of a 43-year-old woman with the history of severe alcohol abuse, who demonstrated typical picture of Marchiafava-Bignami disease (MBD) with fatal course. We reviewed the literature on cases of MBD.

Adult↗
PubMed2005

Relationship between class I and II HLA antigens in schizophrenia and eye movement disturbances: a preliminary study.

The region coding human leukocyte antigen (HLA) on chromosome 6q21 was shown to be associated with both the vulnerability to schizophrenia and presence of eye movement disturbances (EMD). The aim of this preliminary study was to investigate how individual class I and II HLA antigens in schizophrenic patients may be related to schizophrenia and to the intensity of two kinds of EMD: fixation and smooth pursuit. The incidence of HLA antigens was compared between 40 schizophrenic patients (17 male, 23 female) and 198 healthy control subjects (112 male, 86 female). In schizophrenic patients, the intensity of EMD assessed by infrared reflectometry and quantified on a scale from 0 to 3 was correlated with the incidence of HLA antigens. A number of differences regarding HLA antigens were found between schizophrenic patients and healthy subjects. Significant correlation was also obtained between some EMD and a number of HLA antigens. Antigens A24 and A28 were found to occur in different frequencies in schizophrenic patients and healthy control subjects. They also correlated with EMD on the fixation and smooth pursuit tests. The results obtained show an association between HLA antigens and EMD as an endophenotypic marker of schizophrenia, and may add to other findings on susceptibility loci for schizophrenia on chromosome 6p21. A limitation of this study is a small number of investigated patients with schizophrenia.

Adolescent↗
PubMed2005

One-year treatment of Alzheimer's disease with acetylcholinesterase inhibitors: improvement on ADAS-cog and TMT A, no change or worsening on other tests.

The aim of this study was to assess cognitive functioning measured by selected psychometric and neuropsychological tools in patients with Alzheimer's disease (AD) after 1-year treatment with acetylcholinesterase inhibitors. Seventy-six patients (22 male and 54 female) with a mild to moderate stage of AD, aged 56-86 (mean 68) years, were treated. Forty-seven received donepezil (mean dose 9.3 mg/d) and 29 rivastigmine (mean dose 8.5 mg/d). Cognitive measurements included: the mini mental state examination (MMSE), the Alzheimer disease assessment scale-cognitive (ADAS- cog), the trail making test (TMT) and the Stroop color word interference test. The assessments were made before and after 3, 6 and 12 months of treatment. A significant improvement in ADAS-cog (p < 0.001, 83% of patients improved) and a worsening in MMSE (84% of patients worsened, p < 0.01 after 6 and 12 months) was noted after the 1 year treatment. A majority of patients (57%) improved in the TMT-A (p < 0.001), measuring psychomotor speed and worsened in the TMT-B (p < 0.01, after 12 months), and Stroop B test (p < 0.001), measuring working memory and executive functions, 53% and 61%, respectively. Most patients (83%) did not change their performance in the Stroop A (improvement after 3 months, p < 0.001, worsening after 6 and 12 months p < 0.01) test measuring verbal abilities, after 1 year treatment. The results obtained suggest that the treatment with cholinergic drugs may improve global cognitive functioning (ADAS-cog) and psychomotor speed (TMT A), however, such treatment is unable to prevent the deterioration of working memory and executive functions.

Aged↗
PubMed2005

[Evaluation of the intensity of stress at work and burnout syndrome in the managers].

BACKGROUND: Burn out syndrome is connected with the intensity of stress at work. It is a common problem among people who work in management departments. This significantly decreased the effectiveness of work and the quality of psychosocial functioning. The purpose of the study was to establish the dependence between occupational stress and burnout syndrome in the group of managers. MATERIAL AND METHODS: The studied group consisted of 73 managers, aged 27-55 years. The Perceived Job Stress Questionnaire and Maslach Burnout Inventory (MBI) were used in this study. RESULTS: The data obtained revealed significant intensity of stress filling at work in evaluated group. The most stressful factors occur: psychical balance of work, lack of rewards, social contacts and uncertainty at work. The highest risk of burnout syndrome is associated with symptoms of emotional exhaustion and depersonalization. CONCLUSIONS: Higher intensity of occupational stress is connected with the greater intensification of burnout syndrome in investigated group of managers.

Adaptation, Psychological↗
PubMed2003

Polymorphism of the brain-derived neurotrophic factor gene and performance on a cognitive prefrontal test in bipolar patients.

OBJECTIVES: The aim of the study was to test a possible association between the Val66Met polymorphism of the brain-derived neurotrophic factor (BDNF) gene and performance on a neurocognitive test, the Wisconsin Card Sorting Test (WCST), in bipolar patients. METHODS: Fifty-four bipolar patients were studied, 18 male and 36 female, aged 18-72 (mean 46 years). The number of perseverative errors (WCST-P), non-perseverative errors (WCST-NP), completed corrected categories (WCST-CC), conceptual level responses (WCST-%CONC) and set to the first category (WCST-1st CAT) were measured in relation to the Val66Met genotypes of BDNF. RESULTS: The percentages of subjects with Val/Val, Val/Met and Met/Met genotypes were respectively 81.5, 16.7 and 1.8%. Subjects with Val/Val and Val/Met genotypes did not differ on clinical factors except for the age of onset of the illness, which was earlier in Val/Val than Val/Met genotype (27 years versus 38 years). The performance in all domains of WCST was significantly better in subjects with Val/Val BDNF genotype compared with Val/Met genotype. CONCLUSIONS: The results suggest a role of BDNF in prefrontal cognitive function in bipolar illness. The tests of prefrontal cognition may be considered as endophenotypic markers in bipolar illness.

Adolescent↗
PubMed2003

The study of cytosolic phospholipase A2 gene polymorphism in schizophrenia using eye movement disturbances as an endophenotypic marker.

Phospholipase A(2) (PLA2) is a key enzyme of the phospholipid metabolism which shows alteration in schizophrenia. Eye movement disturbances occur in a majority of patients with schizophrenia and in a proportion of their first-degree relatives, and they have been suggested as an endophenotypic marker in genetic studies of this illness. Here we report an association between the BAN I polymorphism of the cytosolic PLA2 gene (single nucleotide polymorphism in the first intron of the gene) and the intensity of eye movement disturbances (fixation and smooth pursuit) observed in 126 schizophrenic patients. The mean intensity of both kinds of eye movement disturbances was significantly higher in individuals homozygous for the A2 genotype compared with the remaining phenotypes. There was also a trend for greater A2 allele frequency in schizophrenic patients with a higher degree of eye movement disturbances. The relative frequency of the A2/A2 genotype was higher in patients with a greater degree of eye movement disturbances occurring during both fixation and smooth pursuit tests. Our results correspond to the other studies showing an association between the cPLA2 polymorphism and schizophrenia (predominance of the A2 allele in schizophrenic subjects).

Adolescent↗
PubMed2003

The frontal lobe neuropsychological tests in patients with schizophrenia and/or obsessive-compulsive disorder.

This study compared the performances of matched schizophrenia patients with or without obsessive-compulsive (OC) symptoms, patients with obsessive-compulsive disorder (OCD), and control subjects on selected frontal lobe tests. Schizophrenic patients without OC were the most impaired; and OCD patients were the least, while schizophrenic patients with OC scored between these two groups.

Adult↗
PubMed2002

Eye movement disturbances in schizophrenia and a polymorphism of catechol-O-methyltransferase gene.

Previous studies suggested an association between the catechol-O-methyltransferase (COMT) Val/Met polymorphism and the performance on neuropsychological tests, measuring prefrontal function in schizophrenia. The aim of this study was to examine the relationship between this polymorphism and performance on oculomotoric tests in schizophrenic patients. The intensity of eye movement disturbances on fixation and smooth pursuit tests and the Val/Met polymorphism of COMT gene were studied in 117 schizophrenic patients (74 male and 43 female). In male schizophrenic patients, the mean intensity of both kinds of eye movement disturbances was lower in subjects who had the Met/Met genotype, with significant difference compared to other genotypes. Also, a significantly higher frequency of the Met allele and the Met/Met genotype was found in male schizophrenic patients exhibiting a lower intensity of smooth pursuit disturbances, and a trend in this direction was observed for the intensity of fixation disturbances. No such relationship was found in female schizophrenic patients. The results obtained suggest that, in male schizophrenic patients the Met allele of the COMT Val/Met polymorphism may have an alleviating effect on eye movement disturbances. They also point to possible gender differences as to the role of COMT in brain function in schizophrenia.

Adolescent↗
PubMed2002

Eye movement and neuropsychological studies in first-degree relatives of schizophrenic patients.

The aim of the study was to compare the results of oculomotor and neuropsychological tests in first-episode schizophrenic patients, in both their parents and matched healthy controls. Eye movement tests included fixation and a smooth pursuit task and neuropsychological tests which comprised the Trail Making Test (TMT) A and B, the Stroop Test A and B, and the Wisconsin Card Sorting Test (WCST). There was a significant difference between the 21 patients and their 33 healthy parents in the results of both the eye movement tests and the TMT and WCST but not in the Stroop test. On the other hand, a significant difference between parents and their matched control subjects was found in both oculomotor tests, in the Stroop B, and in two indices of the WCST (completed categories, CC and percentage of conceptual level responses, %CONC). A correlation was obtained between patients and their fathers in the intensity of smooth pursuit disturbances and two indices of the WCST (CC and %CONC), but not between patients and their mothers. The results obtained confirm those of other studies pointing to the presence of a significant impairment on oculomotor and neuropsychological tests in first-degree nonpsychotic relatives (parents) of schizophrenic patients, which may be used as an endophenotypic markers of genetic predisposition to schizophrenia.

Adolescent↗
PubMed2002

Does risperidone act better in schizophrenic patients who have a family or obstetric history?

PURPOSE: The aim of the study was to assess the effect of treatment with risperidone on psychopathological symptoms and cognitive deficits in schizophrenic patients, in relation to family history, obstetric complications and duration of the illness. METHODS: Fifty schizophrenic inpatients (29 males, 21 females), aged 16-50 (mean 28 years), with duration of the illness 1-15 (mean 4 years) who successfully completed a 3-month risperidone treatment were included into the study. Family history of psychiatric illness and the presence of obstetric complications were estimated by a semistructured questionnaire. Schizophrenic symptoms were assessed using the Positive and Negative Symptoms Scale (PANSS). Cognitive abilities were measured by neuropsychological "frontal lobe" tests: Trail Making Test (TMT), part B, Stroop Color Word Interference Test, part B, and Wisconsin Card Sorting Test (WCST). The clinical and neuropsychological evaluation was performed before and after 3 months of risperidone treatment, in doses 2-6 mg (mean 4.2 mg/day). RESULTS: Before treatment, patients with family history had significantly higher intensity of negative symptoms, and obtained worse results on WCST perseverative errors (PE) and correct categories (CC). These measures were also impaired in subjects with obstetric complications. Additionally, in patients with obstetric complications, total and general PANSS psychopathology was higher and the results of Stroop B were worse. After a 3-month treatment with risperidone, no difference between respective groups was observed both in psychopathology and in neuropsychological tests. Patients with obstetric complications had higher degree of improvement on positive and negative symptoms and on TMT-B than the remaining ones. Patients with longer duration of the illness had less improvement on positive symptoms with risperidone treatment. CONCLUSIONS: The results of this study show that treatment with risperidone results in better compensation of psychopathological (negative symptoms) and neuropsychological (working memory) deficits in patients who have a family history and/or obstetric complications. This may be due to a favourable effect of risperidone on the prefrontal cortex dysfunction mediating these deficits.

Adolescent↗
PubMed2002

Risperidone treatment of schizophrenia: improvement in psychopathology and neuropsychological tests.

The aim of the study was to assess the effects of short-term risperidone treatment on schizophrenic symptoms and on neuropsychological frontal tests, and to find an association between the improvements in these two kinds of domains. Twenty-two schizophrenic patients treated with risperidone (2-6 mg/day) for 4 weeks were studied. Treatment with risperidone resulted in a significant decrease in the intensity of schizophrenic symptoms and in an improvement in all neuropsychological tests applied. A robust correlation was obtained between the amelioration of negative symptoms and improvements in many neuropsychological tests, specifically with amelioration in the Wisconsin Card Sorting Test (WCST), perseverative errors. Some correlation was also found with the improvement of positive symptoms, specifically with amelioration in the WCST, completed categories. The results may suggest a common neurobiological substrate of negative and cognitive symptoms, reflected in prefrontal cortex pathology and in therapeutic response to atypical antipsychotics.

Adolescent↗
PubMedDate not supplied

[Factors connected with the effect of risperidone on psychopathological symptoms and working memory in schizophrenia].

The aim of the study was to assess the impact of some clinical factors such as family history of psychiatric illness, obstetric complications and duration of the illness on the effect of treatment with risperidone on psychopathological symptoms and deficits of working memory in patients with schizophrenia. The study involved 50 patients with schizophrenia, aged 16-50 years (mean 28 years), with duration of the illness 1-15 years (mean 4 years). The clinical and neuropsychological evaluation was performed before and after 3 months of risperidone treatment in dose 2-6 mg (mean 4.2 mg/day). Before treatment, a significantly higher intensity of psychopathological symptoms and of some cognitive dysfunctions was found in schizophrenic patients with family history of psychiatric illness and in those with a history of obstetric complications. After 3 months of risperidone treatment, no difference in the intensity of psychopathological symptoms or the performance on neuropsychological tests was observed among these groups. Patients with longer duration of the illness had less improvement in positive symptoms. The results of this study show that treatment with risperidone may lead to better compensation of psychopathology and of neuropsychological deficits originating in genetic predisposition and obstetric complications. Better effect of risperidone on psychotic symptoms is likely with the administration of the drug early in the course of the illness.

Adolescent↗
PubMedDate not supplied

[The effect of sertraline on cognitive functions in patients with obsessive-compulsive disorder].

The aim of this study was to assess the effect of sertraline on psychopathological symptoms and cognitive functions and in patients with obsessive compulsive disorder (OCD). The investigated group consisted of 25 patients with OCD (12 male, 13 female) aged 17-47 (mean 29 +/- 9) years, duration of illness was 1-15 (mean 4 +/- 2) years. After treatment with sertraline, a significant improvement in OCD symptoms measured by YBOCS and in neuropsychological "frontal" tests were observed. Little correlation was found between the effect of sertraline on OCD symptoms and on cognitive dysfunctions. This may suggest that these two effects may be connected with different pharmacological properties of the drug. The effect of sertraline on OCD symptoms, similarly like other drugs inhibiting serotonin transporter (clomipramine, other SSRI) is associated with its influence on serotonergic system. On the other hand, the effect of sertraline on dopaminergic neurotransmission may be related to its favorable action on cognitive functions connected with the activity of frontal lobe.

Adolescent↗
PubMedDate not supplied

[The case of a patient with treatment-refractory obsessive-compulsive disorder operated by stereotactic bilateral cingulotomy].

This case report presents the first patient in Poland with treatment-refractory obsessive-compulsive disorder, operated by stereotactic bilateral cingulotomy. The patient, aged 38 years, with 20-year duration of illness, despite intensive pharmacological and psychotherapeutic treatment was totally unable to function due to obsessive-compulsive symptoms of extreme intensity. The paper presents the neuroimaging documentation of psychosurgery performed on 3rd December 2002. On the basis of nearly two-year follow-up of the patient, the result of the psychosurgery can be assessed as moderately favorable. The patient's subjective mood and social functioning have improved, as well as his cognitive functions measured by means of neuropsychological tests. In patients with severe, chronic and treatment-refractory obsessive-compulsive disorder psychosurgical treatment may be a therapeutic option.

Adult↗